Product Program year 2025 Source: CMS Open Payments

Susvimo

Drug Immunology and Ophthalmology

NDC 50242-078-12

Open in the dashboard

General payments

$2,298,320

5,864 payments

Research payments

$58,587,872

4,783 payments

Through program year 2025, $2,298,320 in general payments and $58,587,872 in research payments were reported against Susvimo (Immunology and Ophthalmology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

9 rows
Year Kind Amount Payments
2025 General $788,137 1,533
2025 Research $19,508,287 1,637
2024 General $405,097 826
2024 Research $15,418,943 1,505
2023 General $316,773 405
2023 Research $22,949,689 1,592
2022 General $672,645 2,352
2021 General $115,668 748
2021 Research $710,953 49

Breakdown

Who paid General payments · program years 2021–2025
  1. Genentech USA, Inc. $1,812,576 5,087 payments
  2. Genentech, Inc. $298,079 721 payments
  3. F. Hoffmann-La Roche AG $132,288 34 payments
  4. Roche Products Limited $44,142 18 payments
  5. Hoffmann-La Roche Limited $11,234 4 payments
Top recipients General payments · program year 2025
  1. Jordan Graff Retina Specialist · Phoenix, AZ $90,744 12% · 75 payments
  2. Gregory Lee Ophthalmology · Cumming, GA $58,950 7% · 70 payments
  3. Jeremy Wolfe Retina Specialist · Royal Oak, MI $57,515 7% · 32 payments
  4. Deepika Malik Retina Specialist · Woodbury, NY $38,893 5% · 48 payments
  5. John Kitchens Retina Specialist · Lexington, KY $35,057 4% · 24 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Retina Specialist Ophthalmology $476,842 61% · 245 practitioners
  2. Ophthalmology $294,256 38% · 334 practitioners
  3. Optometrist $1,919 <1% · 26 practitioners
  4. Glaucoma Specialist Ophthalmology $355 <1% · 4 practitioners
  5. Ophthalmic Plastic and Reconstructive Surgery Ophthalmology $309 <1% · 3 practitioners

The top 5 of 20 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Iowa $90,878 12% · 3 recipients
  2. California $89,360 11% · 80 recipients
  3. Maryland $70,553 9% · 36 recipients
  4. Georgia $68,828 9% · 28 recipients
  5. Michigan $67,260 9% · 36 recipients

The top 5 of 49 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to SUSVIMO
Billing code Providers Services Paid by Medicare
Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg J2779 2 3,300 $206,473

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

5,864 general · 4,783 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record